Welcome!

News Feed Item

Coronary Thrombosis Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Thrombosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/652973/Coronary-Thrombosis-Global-Clinical-Trials-Review-H2-2014.html

Coronary Thrombosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Thrombosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary Thrombosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Thrombosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Thrombosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 3
List of Figures 4
Introduction 5
Coronary Thrombosis 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Unaccomplished Trials of Coronary Thrombosis 20
Subjects Recruited Over a Period of Time 21
Clinical Trials by Sponsor Type 22
Prominent Drugs 23
Clinical Trial Overview of Top Institutes / Government 24
Hopital de la Timone 24
Clinical Trial Overview of Hopital de la Timone 24
Fujian Provincial Hospital 25
Clinical Trial Overview of Fujian Provincial Hospital 25
Herz-Zentrum Bad Krozingen 26
Clinical Trial Overview of Herz-Zentrum Bad Krozingen 26
University of Zurich 27
Clinical Trial Overview of University of Zurich 27
NHS Greater Glasgow and Clyde 28
Clinical Trial Overview of NHS Greater Glasgow and Clyde 28
Samsung Medical Center 29
Clinical Trial Overview of Samsung Medical Center 29
Hamilton Health Sciences 30
Clinical Trial Overview of Hamilton Health Sciences 30
Odense University Hospital 31
Clinical Trial Overview of Odense University Hospital 31
Universitaire Ziekenhuizen Leuven 32
Clinical Trial Overview of Universitaire Ziekenhuizen Leuven 32
Assistance Publique - Hopitaux de Paris 33
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 33
Five Key Clinical Profiles 34
Appendix 51
Abbreviations 51
Definitions 51
Research Methodology 52
Secondary Research 52
About GlobalData 53
Contact Us 53
Disclaimer 53
Source 53

List of Tables
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Region, 2014* 6
Coronary Thrombosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Thrombosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Thrombosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Coronary Thrombosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 10
Coronary Thrombosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 12
Coronary Thrombosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Coronary Thrombosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 15
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Phase, 2014* 16
Coronary Thrombosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 17
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Coronary Thrombosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 19
Coronary Thrombosis Therapeutics, Global, Terminated Clinical Trials, 2014* 20
Coronary Thrombosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 21
Coronary Thrombosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 22
Coronary Thrombosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 23
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hopital de la Timone, 2014* 24
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Fujian Provincial Hospital, 2014* 25
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Herz-Zentrum Bad Krozingen, 2014* 26
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Zurich, 2014* 27
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by NHS Greater Glasgow and Clyde, 2014* 28
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Samsung Medical Center, 2014* 29
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamilton Health Sciences, 2014* 30
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Odense University Hospital, 2014* 31
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Universitaire Ziekenhuizen Leuven, 2014* 32
Coronary Thrombosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014* 33

List of Figures
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Coronary Thrombosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Coronary Thrombosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Coronary Thrombosis Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Coronary Thrombosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 10
Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 12
Coronary Thrombosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Coronary Thrombosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Proportion of Coronary Thrombosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 15
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 16
Coronary Thrombosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 17
Coronary Thrombosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Coronary Thrombosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 21
Coronary Thrombosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 22
GlobalData Methodology 52

Read the full report:
Coronary Thrombosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/652973/Coronary-Thrombosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Onalytica. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
"We are an all-flash array storage provider but our focus has been on VM-aware storage specifically for virtualized applications," stated Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
"IoT is going to be a huge industry with a lot of value for end users, for industries, for consumers, for manufacturers. How can we use cloud to effectively manage IoT applications," stated Ian Khan, Innovation & Marketing Manager at Solgeniakhela, in this SYS-CON.tv interview at @ThingsExpo, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
We are always online. We access our data, our finances, work, and various services on the Internet. But we live in a congested world of information in which the roads were built two decades ago. The quest for better, faster Internet routing has been around for a decade, but nobody solved this problem. We’ve seen band-aid approaches like CDNs that attack a niche's slice of static content part of the Internet, but that’s it. It does not address the dynamic services-based Internet of today. It does...
Internet of @ThingsExpo, taking place June 6-8, 2017 at the Javits Center in New York City, New York, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo New York Call for Papers is now open.
What happens when the different parts of a vehicle become smarter than the vehicle itself? As we move toward the era of smart everything, hundreds of entities in a vehicle that communicate with each other, the vehicle and external systems create a need for identity orchestration so that all entities work as a conglomerate. Much like an orchestra without a conductor, without the ability to secure, control, and connect the link between a vehicle’s head unit, devices, and systems and to manage the ...